It was learned from the Shanghai Government Network that the “Development Center for High-Rise Tumor and Genetic Diseases Genetic Testing Center†of the National Development and Reform Commission's Gene Detection Technology Application Demonstration Center was launched in Shanghai recently. The third-party biomedical testing organization within the base will be affiliated with Fudan University. The Cancer Hospital, the Shanghai Children's Hospital affiliated to Shanghai Jiaotong University, and the Chest Hospital of Shanghai Jiaotong University have joined forces to provide patients with true precision treatment through genetic testing.
Genetic testing refers to the technique of detecting DNA by blood, body fluids or cells. At present, more than 1,000 diseases can be diagnosed by genetic testing technology, and the most widely used is the detection of neonatal hereditary diseases and prevention of birth defects. The completion of the high-yield tumor and genetic disease genetic testing demonstration center will help to improve the prevention and treatment of major diseases such as genetic diseases and tumors, and has great economic and social significance.
Analysts said that under the strong support of national policies and the huge development space of the industry, the gene sequencing industry will usher in a golden period of development, and related listed companies in A-shares are also expected to obtain a valuation premium at the same time.
A-share precision medical sector opportunity to sort out:
1. Anke Bio: Precision Medicine + Anticancer Faucet
2, Dean diagnosis: precision medicine + anti-cancer
3, Kehua Biology: Precision Medicine + Tumor Detection
4, new open source: precision medicine + anti-cancer
5, Zuoli Pharmaceutical: high starting point layout precision medical
Anesthesia Medical Co., Ltd. , https://www.jssinoanesthesia.com